Press Release

MALVERN, Pa., June 13, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biotechnology company focused on developing innovative products in medical and aesthetic dermatology, today announced that the United States Patent and Trademark Office has issued U.S. Patent 9,675,639 covering the formulation and methods of use of A-101 40% topical solution (A-101 40%), an investigational drug being developed for the treatment of seborrheic keratosis (SK) and A-101 45% topical solution (A-101 45%), an investigational drug being developed for the treatment of common warts. This patent contains 70 claims and expires in July 2035.

The patent is part of an intellectual property portfolio that includes other issued patents and numerous patent applications in the U.S. and major international markets covering high concentration topical hydrogen peroxide formulations, methods of use and applicators for the treatment of certain dermatological conditions, including SK, common warts, molluscum contagiosum, skin tags (acrochordons) and other dermatological conditions. 

“This patent is an important component of Aclaris’ expanding intellectual property portfolio covering both A-101 40% and 45% topical solutions, along with other high concentration formulations and their methods of treating dermatological diseases,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris.

About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.  Aclaris is focused on large, underserved market segments with no FDA-approved medications or where treatment gaps exist.  Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.

About A-101
A-101 40% Topical Solution, an investigational drug, is a proprietary, high-concentration hydrogen peroxide formulation for the treatment of SK. It is being developed as a non-invasive, in-office treatment administered by physicians or other licensed health care professionals.  In clinical trials, patients treated with A-101 40% achieved statistically and clinically significant improvement in clearing SK lesions compared to placebo and with a similar adverse event profile. A-101 40% is designed to work by penetrating into the SK lesion and causing oxidative damage, which can ultimately result in the sloughing of the SK cells.  A-101 40% has been the focus of a robust clinical development program in which over 700 patients have been treated with A-101. A-101 45% is also in clinical development for the treatment of common warts (verruca vulgaris).

Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations.  These forward-looking statements include expectations regarding Aclaris’ clinical development of A-101 for the treatment of SK and common warts. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, risks associated with maintaining its intellectual property portfolio and other risks and uncertainties that are described in Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2016, Aclaris’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, and other filings Aclaris makes with the SEC from time to time. These documents are available under the “Financial Information” section of the Investors page of Aclaris’ website at http://www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Aclaris Contact
Michael Tung, M.D.
Investor Relations
484-329-2140
mtung@aclaristx.com

Media Contact
Mariann Caprino
TogoRun
917-242-1087
M.Caprino@togorun.com

Aclaris Therapeutics, Inc.